WinstonWınston
Back
Vita Life Sciences Limited logo

Vita Life Sciences Limited

VLS.AX
71
Drug Manufacturers - Specialty & Generic · Healthcare
Exchange
Australian Securities Exchange
Winston Score
71
Winston is happy
A high-quality business with solid fundamentals.
Data as of Aug 23, 2026 · filings through Dec 31, 2025
How the score breaks down
Quality
Strong
Growth
Good
Cash Flow
Exceptional
Stability
Good
Valuation
Good
Dividends
Exceptional

Winston Score History

The full picture

Vita Life Sciences is an Australian healthcare company that makes and sells vitamins, supplements, and health products. Its core products include vitamins, minerals, herbal remedies, and traditional medicines sold under its own brands. The company sells mainly to pharmacies, health food stores, and consumers across Australia and several Asian markets.

The company makes money by manufacturing and distributing its branded health products, earning revenue each time a retailer or consumer buys them. It operates primarily in Australia, Singapore, Malaysia, and other parts of Southeast Asia, giving it a foothold in markets where demand for health supplements is growing. Its relatively high gross margin of around 61% suggests some pricing power from its established brands, but it is a small company competing against much larger global supplement makers. The key growth driver is expanding its presence in Asian markets, where rising incomes and growing health awareness are increasing demand for vitamins and supplements.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+19.2% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+23.0% YoY

YoY Growth Rate

Steady EPS growth

Insider Activity

77.3%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

A$36M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Vita Life Sciences Limited is a rare growth stock that's already generating positive cash flow while growing at 19%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
62.1%
Premium pricing power — 62.1% gross margin
Profit after running costs
Operating Margin
16.1%
Healthy — 16.1% operating margin
Return on the money invested
ROCE
26.1%
Exceptional — 26.1% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+17.3%
Fast-growing sales (+17.3% YoY)
Profit growth
EPS YoY
+16.7%
Earnings growing fast (+16.7% YoY)

Healthy double-digit earnings growth — what compounders look like.

How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
157%
Turns 157% of profit into real cash
Spare cash per sale
FCF Margin
16.7%
Converts sales into free cash efficiently (16.7%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
41.52x
Comfortably covers interest (41.5x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
14.8x
no trend
Attractive valuation — P/E 14.8

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
6.93%
no trend
Healthy income — 6.93% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend record
Dividend Growth
+60.0%
no trend
Dividend growing fast (60.0% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial